The UCLA Health study in Nature Communications found that a single dose of rapamycin rapidly improved brain signaling and reduced autism‑like behaviors in adult mice exposed to prenatal inflammation, with measurable changes within two hours. Researchers report rapamycin calmed hyperactive neurons and reversed abnormal gene‑expression patterns tied to autism and epilepsy. However, effects were temporary, repeated dosing caused tolerance and toxicity, and authors emphasize the findings point to new therapeutic targets rather than rapamycin as a clinical treatment.
Single Rapamycin Dose Rapidly, Temporarily Reverses Autism‑Like Behaviors in Adult Mice, UCLA Study Finds
Researchers reverse autism-like symptoms in mice with one drug dose
Researchers at UCLA Health report that a single dose of the immunosuppressant rapamycin produced rapid, temporary improvements in brain signaling and autism‑like behaviors in adult mice exposed to prenatal inflammation. The study, published in Nature Communications, highlights new molecular and circuit targets for therapies while emphasizing that rapamycin itself is unlikely to be a safe clinical treatment for autism.
Pregnant mice were given a mild inflammatory stimulus to model maternal immune activation, which prior research links to increased risk of neurodevelopmental changes in offspring. The offspring developed persistent inflammation in the brain and body and displayed features described as autism‑like in rodents: altered brain growth, seizures, repetitive behaviors and heightened sensory sensitivity.
When adult offspring showing these behaviors received a single dose of rapamycin, researchers observed measurable changes within two hours. Electrophysiological recordings and behavioral tests showed that rapamycin calmed hyperactive neurons, reduced repetitive behaviors and eased sensory overresponsivity. Regions of the brain that had been poorly synchronized began to show more typical patterns of communication.
To probe how such rapid changes occurred, the team analyzed gene activity in brain cells before and after treatment. They concluded that rapamycin altered electrical activity and patterns of gene expression rather than repairing structural brain changes—processes that typically require longer timeframes. The drug reversed abnormal gene‑expression patterns linked to both autism and epilepsy in this model.
What Rapamycin Is
Rapamycin (also called sirolimus) is a prescription immunosuppressant and an inhibitor of the mechanistic target of rapamycin (mTOR). mTOR is a key cellular regulator of growth, metabolism and survival. Rapamycin is used clinically to prevent organ‑transplant rejection and has been studied experimentally for aging and certain seizure disorders.
“The level of functional normalization achieved over this short time suggests new mechanisms by which possible treatments may act,” said study senior author Dr. Harley Kornblum. “It suggests the adult brain may be more adaptable than we assumed, even when the underlying structural changes from early development are still there.”
Despite the promising acute response, important caveats limit clinical optimism. The effects were transient: benefits faded, mice developed tolerance after repeated dosing, and prolonged use produced toxicity. For these reasons the authors caution that rapamycin itself is unlikely to be pursued as a routine treatment for autism. Co‑senior author Dr. Neil Harris said the findings are most valuable as a guide to new therapeutic strategies—such as sensory‑circuit neuromodulation or approaches that rebalance neuronal excitation and inhibition—rather than a direct endorsement of rapamycin for patients.
Implications and Next Steps
This study points to fast‑acting, reversible changes in neural function that could be targeted by safer, more specific interventions. Further research is needed to translate these mechanistic insights into human‑relevant therapies and to evaluate long‑term safety and efficacy in models more closely aligned with human neurodevelopment.
Help us improve.
